Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Catalent | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Catalent

Oral Technologies revenue up 4% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Catalent

4Q Revenues: $519.6 million (+3%)

4Q Earnings: $27.2 million (+66%)

FY Revenues: $1.8 billion (+2%)

FY Earnings: $16.2 million (loss of $49.6 million FY13)

Comments: Revenue from the Oral Technologies segment was $348.1 million, up 4% in the quarter led by the softgel business in international markets, and partially offset by volume declines in the pharma softgel business in North America and the company’s exit from its third-party commercial packaging business. Revenue from the Development and Clinical Services segment was $105.4 million, down 1% primarily due to lower comparator sales. Revenue from the Medication Delivery Solutions segment was $68.9 million, up 1%. The company recenlty announced plans to open a lab in Japan to provide proof-of-concept support and feasibility studies for the proprietary Zydis platform.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters